MRK Stock Recent News

Given its attractive valuation, we believe Pfizer stock (NYSE: PFE) is a better pick than its peer — Merck stock (NYSE: MRK). MRK trades at a higher valuation multiple of 5.6x revenues vs.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Merck (MRK) reachead $131.95 at the closing of the latest trading day, reflecting a +0.15% change compared to its last close.

Jerry Castellini, Castle Ark Management president and CIO, joins 'Power Lunch' to discuss Castellini's investing take on three stocks: Tesla, Merck, and RH.

Merck & Co Inc (NYSE:MRK, ETR:6MK) shares traded more than 4% higher after it won US Food and Drug Administration (FDA) approval for its lung disorder drug sotatercept, brand name WINREVAIR.  After being granted breakthrough therapy designation by the agency, the drug is now the first FDA-approved activin signalling inhibitor therapy for pulmonary arterial hypertension (PAH), a rare, progressive and life-threatening disease where the blood vessels in an individual's lungs thicken and narrow and cause strain on the heart.

Merck & Co Inc  (NYSE:MRK) was last seen up 4.4% to trade at $130.99, after the Food and Drug Administration (FDA) approved its Winrevair treatment for adults with high blood pressure due to constriction of lung arteries.

Zacks.com users have recently been watching Merck & Co. (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Merck's (MRK) Winrevair becomes the first novel activin signaling inhibitor approved by the FDA to treat PAH.

Merck shares gain 5% to $131.90 in afterhours trading following approval of its new drug for a potentially fatal lung disease.

The approval is a win for Merck, which is working to diversify its revenue stream as its blockbuster cancer drug Keytruda nears a loss of market exclusivity.